124 related articles for article (PubMed ID: 34875275)
1. Research progress on the potential novel analgesic BU08028.
Wang Y; Qin D; Guo Z; Shi F; Cannella N; Ciccocioppo R; Li H
Eur J Pharmacol; 2022 Jan; 914():174678. PubMed ID: 34875275
[TBL] [Abstract][Full Text] [Related]
2. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
3. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
Flynn SM; Epperly PM; Davenport AT; Cami-Kobeci G; Husbands SM; Ko MC; Czoty PW
Neuropsychopharmacology; 2019 Jul; 44(8):1476-1484. PubMed ID: 30970376
[TBL] [Abstract][Full Text] [Related]
4. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
5. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
7. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
Coluzzi F; Rullo L; Scerpa MS; Losapio LM; Rocco M; Billeci D; Candeletti S; Romualdi P
CNS Drugs; 2022 Jun; 36(6):617-632. PubMed ID: 35616826
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
9. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance.
Bossert JM; Townsend EA; Altidor LK; Fredriksson I; Shekara A; Husbands S; Sulima A; Rice KC; Banks ML; Shaham Y
Br J Pharmacol; 2022 Jan; 179(2):227-241. PubMed ID: 34505281
[TBL] [Abstract][Full Text] [Related]
11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
12. Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies.
Chen R; Coppes OJM; Urman RD
Pain Physician; 2021 Mar; 24(2):153-163. PubMed ID: 33740349
[TBL] [Abstract][Full Text] [Related]
13. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
14. Peripherally acting opioid analgesics and peripherally-induced analgesia.
Martínez V; Abalo R
Behav Pharmacol; 2020 Apr; 31(2&3):136-158. PubMed ID: 32168025
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].
Bono AV; Cuffari S
Drugs; 1997; 53 Suppl 2():40-9. PubMed ID: 9190324
[TBL] [Abstract][Full Text] [Related]
16. On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance.
Fürst S; Zádori ZS; Zádor F; Király K; Balogh M; László SB; Hutka B; Mohammadzadeh A; Calabrese C; Galambos AR; Riba P; Romualdi P; Benyhe S; Timár J; Schmidhammer H; Spetea M; Al-Khrasani M
Molecules; 2020 May; 25(11):. PubMed ID: 32466522
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional μ opioid and σ
Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
[TBL] [Abstract][Full Text] [Related]
18. Opioid utility function: methods and implications.
van Dam CJ; Algera MH; Olofsen E; Aarts L; Smith T; van Velzen M; Sarton E; Niesters M; Dahan A
Ann Palliat Med; 2020 Mar; 9(2):528-536. PubMed ID: 31865743
[TBL] [Abstract][Full Text] [Related]
19. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.
Davis MP
J Support Oncol; 2012; 10(6):209-19. PubMed ID: 22809652
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
